StockNews.com Begins Coverage on TherapeuticsMD (NASDAQ:TXMD)

StockNews.com initiated coverage on shares of TherapeuticsMD (NASDAQ:TXMD) in a research note issued on Wednesday. The brokerage set a “hold” rating on the stock.

TherapeuticsMD Price Performance

NASDAQ TXMD opened at $1.14 on Wednesday. The stock has a 50-day simple moving average of $1.31 and a 200 day simple moving average of $1.57. TherapeuticsMD has a twelve month low of $0.70 and a twelve month high of $2.75.

Institutional Investors Weigh In On TherapeuticsMD

An institutional investor recently raised its position in TherapeuticsMD stock. Clearline Capital LP raised its stake in shares of TherapeuticsMD, Inc. (NASDAQ:TXMD) by 18.9% during the 2nd quarter, according to the company in its most recent filing with the SEC. The firm owned 636,622 shares of the company’s stock after purchasing an additional 101,282 shares during the quarter. Clearline Capital LP owned 5.52% of TherapeuticsMD worth $1,025,000 as of its most recent filing with the SEC. Hedge funds and other institutional investors own 30.74% of the company’s stock.

About TherapeuticsMD

TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.